• EOH 2016 Home Slide

  • Slide MSM PrEP

  • Slideshow_hivhealthreform

  • Slide Trans

  • slide_prepvideos

AIDS2016: High engagement, maintenance and meaningful PrEP adherence is possible among black MSM

logo_aids2016_sm

While several previous PrEP studies have found higher dropout rates and poorer adherence among black MSM than white MSM in the United States, continuing reports from the first study designed by and for black MSM shows that the right approach can lead to success and that…Read More

AIDS2016: No HIV transmission events from condomless sex between mixed-HIV-status couples

logo_aids2016_sm

The European PARTNER study is now the second large HIV study to determine that full viral suppression due to antiretroviral therapy renders an HIV-positive person nearly completely uninfectious to their HIV-negative sex partners. The study was published in JAMA prior to the AIDS 2016 conference in…Read More

AIDS2016: Long-acting rilpivirine persists for months in the body

logo_aids2016_sm

A study looking at a long-acting injectible form of the antiretroviral drug rilpivirine revealed that it persists for months after a single dose, most of the time at levels too low to protect against HIV infection, but high enough to cause drug resistance if a person…Read More

AIDS2016: New analysis finds dapivirine vaginal ring might be highly effective at blocking HIV infection

logo_aids2016_sm

A monthly vaginal ring containing the antiretroviral drug dapivirine might offer a protection rate of up to 92% in women who keep the ring inserted for the full duration of each month. The ring, which was studied in 2,629 women in the HPTN-020/ASPIRE study, was previously…Read More

AIDS2016: Four studies address concerns about PrEP in gay and bisexual men

logo_aids2016_sm

A number of significant concerns were raised even before the battle for PrEP approval in the United States began in 2012. Among the most intense fears about PrEP were the possibility that increases in condomless sex among PrEP users would actually lead to more new infections,…Read More

AIDS2016: Two-drug HIV regimen of dolutegravir and lamivudine controls HIV in a small study

logo_aids2016_sm

Researchers reported that a two-drug combination of ViiV Healthcare’s integrase inhibitor dolutegravir (Tivicay) with its NRTI lamivudine (Epivir) produced a sustained reduction in viral loads to less than 50 copies in 18 out of 20 people. Most regimens contain at least three drugs from two different…Read More

AIDS2016: Switching to single pill regimen controls HIV as well as other standard treatment

logo_aids2016_sm

New data show equal control of HIV levels when switching from a standard multi-pill regimen to the single tablet regimen of Triumeq (dolutegravir + abacavir + lamivudine). The STRIIVING study presented 48-week data on switching to Triumeq from various other regimens in people currently on treatment…Read More